Many targeted cancer therapies suppress T cell immune responses

New research has demonstrated that dozens of these targeted therapies suppressed the activity of T cells that could actually help fight tumors. While studying the FDA-approved targeted therapy trametinib, the researchers also found that pairing it with a signaling protein ’superagonist‘ stimulated T cell activity while preserving the cancer-blocking effects of the cancer treatment. (Mehr in: Cancer News — ScienceDaily)